Targeting de novo lipogenesis improves gemcitabine efficacy in pancreatic ductal adenocarcinoma
Sarah E. Hancock, Linda L. Garthwaite, Konstantina Harellis, Michael Susetio, Eileen Ding, Laura L. Y. Choong, Osvaldo Contreras, Amy Nguyen, J. Lising, Felicia Hansen, Puttandon Wongsomboon, Jan Philipp Menzel, Berwyck L. J. Poad, Todd W. Mitchell, Stephen J. Blanksby, Nigel A. Turner
This study identifies de novo lipogenesis as a mechanism of gemcitabine resistance in PDAC and shows that targeting lipid synthesis enzymes enhances treatment efficacy.
bioRxiv · Dec 18, 2024 · PreprintCancer Biology